Global Lifestyle Drugs Market Valued at $110 billion in 2025, Set to Grow at a 6.2% CAGR

Lifestyle drugs market was valued at $110 billion in 2025 and is projected to reach $199.7 billion by 2035, growing at a CAGR of 6.2% during the forecast Period (2026-2035). Regulatory approvals are enhancing innovation in the lifestyle drugs market, encouraging the creation of more effective, higher-dose formulations for chronic weight management, ultimately propelling market growth through next-generation therapies with improved clinical outcomes. For instance, in March 2026, the US FDA approved a higher-dose version of Wegovy (semaglutide) for chronic weight management. The new formulation (up to 7.2 mg) demonstrated significantly greater weight loss compared to earlier doses, strengthening its role in obesity treatment and expanding options for patients who need more effective therapy.

Browse the full report description of “Lifestyle Drugs Market Size, Share & Trends Analysis by Therapeutic Type (Dermatology, Obesity, Sexual Dysfunction, Insomnia, Depression / Anti-depressants, Smoking Cessation, Women’s Health / Contraceptives, and Others), By Drug Form (Tablets, Gels, Oral Syrups, Parenteral (Injectables), Creams, Chewing Gums, and Others), and By End-User (Hospital-based Distribution, Retail Pharmacies / Drug Stores, Online Pharmacies / E-commerce Platforms, Clinics & Specialty Centers, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/lifestyle-drugs-market

FDA Expands Lifestyle Drugs with New Obesity Uses and Oral Therapies

• In March 2026, the FDA approved setmelanotide (Imcivree) for hypothalamic obesity, a rare condition linked to brain injury. This represents an expansion of lifestyle drug applications beyond general obesity into specialized metabolic disorders.
• In December 2025, the FDA approved the first oral GLP-1 drug (Wegovy pill) for weight loss, marking a major shift from injectable therapies to more convenient oral formulations. This approval improves patient accessibility and adherence, accelerating the adoption of lifestyle drugs globally.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Therapeutic Type
  • By Drug Form
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AbbVie Inc., Eli Lilly and Co., Johnson & Johnson, Novo Nordisk A/S, Pfizer Inc., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lifestyle Drugs Market Report Segment

By Therapeutic Type

• Dermatology
• Obesity
• Sexual Dysfunction
• Insomnia
• Depression / Anti-depressants
• Smoking Cessation
• Women’s Health / Contraceptives
• Others

By Drug Form

• Tablets
• Gels
• Oral Syrups
• Parenteral (Injectables)
• Creams
• Chewing Gums
• Others

By End-User

• Hospital-based Distribution
• Retail Pharmacies / Drug Stores
• Online Pharmacies / E-commerce Platforms
• Clinics & Specialty Centers
• Others

Global Lifestyle Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lifestyle-drugs-market